RiverVest’s new Archer Seed Fund will invest pre-seed and seed funding in about 10 early-stage biopharma companies. Investment opportunities will be sourced primarily from leading medical research institutions in St. Louis, the Midwest, and elsewhere in the U.S.
Also in this issue:
Karen Gheesling Mullis joins RiverVest
RiverVest Annual Meeting is April 11, 2017
Portfolio company news from Allakos, Amplyx, Tioma and Tryton